Pathophysiology of the metabolic syndrome

Emma McCracken, Monica Monaghan, Shiva Sreenivasan*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

228 Citations (Scopus)


The metabolic syndrome—otherwise called syndrome X, insulin resistance syndrome, Reaven syndrome, and “the deadly quartet”—is the name given to the aggregate of clinical conditions comprising central and abdominal obesity, systemic hypertension, insulin resistance (or type 2 diabetes mellitus), and atherogenic dyslipidemia. It is a prothrombotic and proinflammatory state characterized by increased inflammatory cytokine activity. In addition to inflammatory dermatoses such as psoriasis, lichen planus, and hidradenitis suppurativa, metabolic syndrome is also commonly associated with accelerated atherosclerotic cardiovascular disease, hyperuricemia/gout, chronic kidney disease, and obstructive sleep apnea. Current therapeutic options for metabolic syndrome are limited to individual treatments for hypertension, hyperglycemia, and hypertriglyceridemia, as well as dietary control measures and regular exercise.

Original languageEnglish
Pages (from-to)14-20
Number of pages7
JournalClinics in Dermatology
Issue number1
Early online date11 Dec 2017
Publication statusPublished - 01 Jan 2018
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2017

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Pathophysiology of the metabolic syndrome'. Together they form a unique fingerprint.

Cite this